Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
79
days
Targeting the epigenetic landscape of ECFCs: a new opportunity to enhance vascular repair
Authors
Yaqiong Liu; Caomhán John Lyons; Christine Ayu Lagonda; Yingquan Luo; Lin Cheng; Zhenfei FangShow moreShow less
Affiliations
1. Second Xiangya Hospital of Central South University; 2. Ollscoil na Gaillimhe – University of Galway; 3. Central South UniversityShow moreShow less
54
days
Anti-angiogenic therapy as potential treatment for adenomyosis
Authors
Marissa J. Harmsen; Lynda J. M. Juffermans; Muara O. Kroon; Arjan W. Griffioen; Judith A. F. HuirneShow moreShow less
Affiliations
1. Department of Obstetrics and Gynaecology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; 2. Amsterdam Reproduction & Development Research Institute, Amsterdam, the Netherlands; 3. Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, The Netherlands; 4. Cancer Center Amsterdam, Amsterdam, The NetherlandsShow moreShow less
160
days
Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor
Authors
Anbukkarasi Muniyandi; Gabriella D. Hartman; Kamakshi Sishtla; Ratan Rai; Cátia Gomes; Kristina Day; Yang Song; Andi R. Masters; Sara K. Quinney; Xiaoping Qi; Hailey Woods; Michael E. Boulton; Jason S. Meyer; Jonah Z. Vilseck; Millie M. Georgiadis; Mark R. Kelley; Timothy W. CorsonShow moreShow less
Affiliations
1. Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, USA; 2. Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, USA; 3. Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, USA; 4. Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, USA; 5. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada; 6. Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, USA; 7. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA; 8. Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, USA; 9. Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, USA; 10. Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, USA; 11. Department of Biology, Indiana University-Purdue University Indianapolis, Indianapolis, USA; 12. Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, USA; 13. Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, USA; 14. Department of Ophthalmology and Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, CanadaShow moreShow less
81
days
A novel quantitative angiogenesis assay based on visualized vascular organoid
Authors
Yun Zhao; Mengze Sun; Zihang Pan; Weijing Kong; Zixuan Hong; Wei Zhang; Bingbing Sun; Jingjing Zhang; Xi Wang; Kai WangShow moreShow less
Affiliations
1. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing, China; 2. TianXinFu (Beijing) Medical Appliance Co., Ltd., Beijing, China; 3. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China; 4. State Key Laboratory of Female Fertility Promotion, Department of Obstetrics and Gynecology, Peking University Third Hospital, Institute of Advanced Clinical Medicine, Peking University, Beijing, ChinaShow moreShow less
88
days
Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial
Authors
Ruben Hermann; Vincent Grobost; Xavier Le-Guillou; Christian Lavigne; Antoine Parrot; Sophie Rivière; Julie Séguier; Anne-Emmanuelle Fargeton; Aurélie de-Montigny; Margaux Huot; Evelyne Decullier; Adeline Roux; Caroline Gervaise; César Cartier; Xavier Dufour; Margaux Grall; Frank Jegoux; Laurent Laccourreye; Justin Michel; Nicolas Saroul; Isabelle Wagner; Mallorie Kerjouan; Sophie Dupuis-GirodShow moreShow less
Affiliations
1. Service d’ORL, chirurgie cervico-faciale et d’audiophonologie, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; 2. Service de Médecine Interne, CHU Estaing, Clermont-Ferrand University Hospital, Clermont-Ferrand, France; 3. Medical Genetics Department, University Hospital of Poitiers, Poitiers, France; 4. Department of Internal Medicine and Clinical Immunology, Angers University Hospital, Angers, France; 5. Assistance Publique-Hôpitaux de Paris, Service de Pneumologie et Centre de Compétence de la Maladie de Rendu Osler, Hôpital Tenon, Paris, France; 6. Service de Médecine Interne A, Centre Hospitalier Universitaire, Montpellier, France; 7. CHU de Montpellier, Hôpital St Eloi, Service de médecine Interne A and Centre d’Investigation Clinique, Inserm, CIC 1411, Montpellier Cedex, France; 8. Aix-Marseille Univ, APHM, Médecine Interne, Hôpital de la Timone, Marseille, France; 9. Service de Génétique et centre de reference de la maladie de Rendu-Osler, Hôpital Femme-Mère-Enfants, Hospices Civils de Lyon, Bron, France; 10. Service de Biostatistique et Bioinformatique des HCL, Lyon, France; 11. Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France; 12. Service de pharmaceutique, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France; 13. Service d’ORL Centre Hospitalier Universitaire, Montpellier, France; 14. Service de Chirurgie ORL, Centre Hospitalier Universitaire de Poitiers, Poitiers, France; 15. Service de Chirurgie ORL, Centre Hospitalier Universitaire Pontchaillou, Rennes, France; 16. Service d’ORL, CHU d’Angers, Angers cedex 9, France; 17. Department of Otorhinolaryngology-Head and Neck Surgery, Aix Marseille University, 36900APHM, IUSTI, La Conception University Hospital, Marseille, France; 18. Service d’ORL, Hôpital Gabriel Montpied, CHU Clermont Ferrand, Clermont-Ferrand, France; 19. Department of Otorhinolaryngology-Head and Neck Surgery, Sorbonne University, Tenon Hospital, AP-HP, Paris, France; 20. Service de Pneumologie, CHU Rennes, Rennes, FranceShow moreShow less
47
days
Circulating endothelial cells: a key biomarker of persistent fatigue after hospitalization for COVID-19
Authors
David M. Smadja; Sven Günther; Pauline Cavagna; Bertrand Renaud; Dominique Salmon; Bertrand Hermann; Brigitte Ranque; Cédric Lemogne; Jean-Luc Diehl; Aurélien PhilippeShow moreShow less
Affiliations
1. Innovative Therapies in Hemostasis, Paris Cité University, INSERM, Paris, France; 2. Hematology Department, AP-HP, Georges Pompidou European Hospital, Paris, France; 3. Unité d’Explorations Fonctionnelles Respiratoires et du Sommeil, AP-HP, Georges Pompidou European Hospital, Paris, France; 4. Pitié-Salpêtrière Hospital, Pharmacy Department, AP-HP, Paris, France; 5. Paris Cité University, INSERM U970, Paris Cardiovascular Research Centre (PARCC), Paris, France; 6. Hôtel-Dieu Hospital, Infectious Diseases and Immunology Department, AP-HP, Paris, France; 7. Medical Intensive Care Department, AP-HP, Georges Pompidou European Hospital, Paris, France; 8. Internal Medicine Department, AP-HP, Georges Pompidou European Hospital, Paris, France; 9. Paris Cité University and Sorbonne Paris Nord University, Inserm, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France; 10. Adult Psychiatry Department, AP-HP, Hôtel-Dieu Hospital, Paris, FranceShow moreShow less
FAQ
How long does ANGIOGENESIS take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for ANGIOGENESIS. The fastest paper went from submission to acceptance in 14 days (Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions, received 2024-11-17, accepted 2024-12-01); the slowest took 160 days. The average is 81.3 days and the median is 79 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
